STAT3 and hepatocellular carcinoma: Ultimately, deletion of hepatic LepR in IL-6Rα-deficient mice further ameliorates DEN-induced HCC development, implicating that downstream STAT3 inhibition might be a pivotal strategy to prevent hepatocarcinogenesis in humans.